Loading...
•
Dec 28, 2024
Haemonetics Q3 2025 Earnings Report
Haemonetics reported third quarter of fiscal year 2025 results and updated fiscal year 2025 guidance.
Key Takeaways
Haemonetics reported a 3.7% increase in revenue compared to the third quarter of fiscal 2024, with a notable 23.9% growth in the Hospital business unit. The company's adjusted earnings per diluted share increased by 14.4% to $1.19, and cash on hand increased by $142.0 million since the end of fiscal 2024.
Third quarter fiscal 2025 revenue was $348.5 million, up 3.7% compared with the third quarter of fiscal 2024.
Earnings per diluted share were $0.74, compared to $0.61 in the same period last year.
Adjusted earnings per diluted share reached $1.19, a 14.4% increase year-over-year.
Cash flow from operating activities was $43.8 million, with free cash flow at $29.6 million.
Revenue by Segment
Forward Guidance
The Company updated its fiscal 2025 GAAP total revenue and organic revenue growth guidance. Adjusted operating margin is expected to be ~24%. Adjusted earnings per diluted share are projected to be $4.50 - $4.70. Free cash flow is anticipated to be $120M - $140M.
Positive Outlook
- Total Company Reported Revenue growth is guided between 3-5%.
- Hospital Reported Revenue growth is guided at 24-26%.
- Adjusted operating margin is expected to be ~24%.
- Adjusted earnings per diluted share are projected to be $4.50 - $4.70.
- Focus on sustained long-term growth across the business.
Challenges Ahead
- Plasma Reported Revenue growth is guided between -5% to -7%.
- Blood Center Reported Revenue growth is guided between -7% to -9%.
- Organic growth is guided between 0-3%.
- Free cash flow is anticipated to be $120M - $140M, lower than previous guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...